[{"data":1,"prerenderedAt":181},["ShallowReactive",2],{"drug-panitumumab":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":34,"contraindications":66,"warnings":67,"renal":82,"monitoring":83,"interactions":84,"review":85,"examples":88,"atc":96,"iran":98,"usApproval":114,"links":120,"populations":137},"panitumumab",1,{"fa":7,"en":8},"پانیتوموماب","Panitumumab","antineoplastic-immunomodulating",{"fa":11,"en":12},"آنتی‌بادی ضد EGFR","EGFR antagonist antibody",[14],{"name":15,"market":16},"Vectibix","US",[18,19,7],"vectibix","وکتیبیکس",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":29,"refs":30},"inj-20","injection","iv","20 mg\u002FmL (100 mg\u002F5 mL, 400 mg\u002F20 mL)",{"amount":27,"unit":28,"perVolumeMl":5},20,"mg",[16],[31],{"source":32,"section":33},"fda-vectibix","3",[35],{"id":36,"disease":37,"label":38,"population":41,"type":45,"unit":28,"dose":46,"refs":49,"durationDays":52,"notes":53},"crc","colorectal-cancer",{"fa":39,"en":40},"سرطان کولورکتال متاستاتیک RAS وحشی — ۶ mg\u002Fkg وریدی هر ۱۴ روز","RAS wild-type metastatic colorectal cancer — 6 mg\u002Fkg IV every 14 days",{"minAge":42},{"value":43,"unit":44},18,"year","weightBased",{"perKgPerDose":47,"intervalHours":48},6,24,[50],{"source":32,"section":51},"2",{"min":5,"max":5},[54,60],{"text":55,"refs":58},{"fa":56,"en":57},"فقط زیر نظر متخصص انکولوژی؛ ادامه تا پیشرفت بیماری یا سمیت غیرقابل‌قبول. تنظیم دوز برای عوارض و تداخل‌ها طبق برچسب.","Only under an oncologist; continue until progression or unacceptable toxicity. Dose adjustments for toxicity and interactions per label.",[59],{"source":32,"section":51},{"text":61,"refs":64},{"fa":62,"en":63},"انفوزیون ۶۰ دقیقه (تا ۱۰۰۰ mg) یا ۹۰ دقیقه (بیشتر). جهش KRAS G12C: همراه سوتوراسیب.","Infuse over 60 min (≤1000 mg) or 90 min (>1000 mg). KRAS G12C: with sotorasib.",[65],{"source":32,"section":51},[],[68,75],{"text":69,"refs":72},{"fa":70,"en":71},"هشدار جعبه‌ای: سمیت پوستی (۹۰٪، شدید ۱۵٪).","Boxed warning: dermatologic toxicity (90%, severe in 15%).",[73],{"source":32,"section":74},"Boxed Warning",{"text":76,"refs":79},{"fa":77,"en":78},"کاهش الکترولیت؛ واکنش انفوزیون؛ نارسایی حاد کلیه؛ بیماری بینابینی ریه؛ حساسیت به نور؛ سمیت چشمی؛ سمیت جنینی.","Electrolyte depletion; infusion reactions; acute renal failure; interstitial lung disease; photosensitivity; ocular toxicity; embryo-fetal toxicity.",[80],{"source":32,"section":81},"5",[],[],[],{"status":86,"reviewer":87,"date":87},"unverified",null,[89],{"regimen":36,"formulation":22,"input":90,"expect":93},{"ageYears":91,"weightKg":92},60,70,{"perDose":94,"mlPerDose":95},420,21,[97],"L01FE02",{"status":99,"forms":100,"refs":109},"registered",[101,105],{"code":102,"en":103,"fa":104},"12541","PANITUMUMAB 20MG\u002FML 20ML AMP","آمپول پانیتومومب ۲۰ میلی‌گرم \u002F میلی‌لیتر ۲۰ میلی‌لیتر",{"code":106,"en":107,"fa":108},"12540","PANITUMUMAB 20MG\u002FML 5ML AMP","آمپول پانیتومومب ۲۰ میلی‌گرم \u002F میلی‌لیتر ۵ میلی‌لیتر",[110],{"source":111,"section":112,"url":113},"darooyab-generic","G-4787\u002FPanitumumab","https:\u002F\u002Fwww.darooyab.ir\u002FG-4787\u002FPanitumumab",{"kind":115,"refs":116,"id":119},"BLA",[117],{"source":32,"section":118},"SPL approval \u002F marketing category","BLA125147",[121,124,128,132,135],{"kind":122,"url":123,"label":119},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=125147",{"kind":125,"url":126,"label":127},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=e0fa4bca-f245-4d92-ae29-b0c630a315c2","FDA Vectibix",{"kind":129,"url":130,"label":131},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa607066.html","Panitumumab Injection",{"kind":133,"url":134,"label":97},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=L01FE02",{"kind":136,"url":113,"label":8},"darooyab",{"pregnancy":138,"lactation":147,"pediatric":155,"geriatric":164,"reproductive":173},{"level":139,"text":140,"quote":143,"refs":144},"avoid",{"fa":141,"en":142},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Risk Summary Based on data from animal studies and its mechanism of action, Vectibix can cause fetal harm when administered to pregnant women [see Clinical Pharmacology (12.1) ] .",[145],{"source":32,"section":146},"8.1",{"level":139,"text":148,"quote":151,"refs":152},{"fa":149,"en":150},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","Because of the potential for serious adverse reactions in breastfed infants from Vectibix, advise women not to breastfeed during treatment with Vectibix and for 2 months after the last dose.",[153],{"source":32,"section":154},"8.2",{"level":156,"text":157,"quote":160,"refs":161},"caution",{"fa":158,"en":159},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of Vectibix have not been established in pediatric patients.",[162],{"source":32,"section":163},"8.4",{"level":165,"text":166,"quote":169,"refs":170},"ok",{"fa":167,"en":168},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in safety or efficacy were observed in elderly patients (≥ 65 years of age) treated with Vectibix monotherapy.",[171],{"source":32,"section":172},"8.5",{"level":156,"text":174,"quote":177,"refs":178},{"fa":175,"en":176},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Contraception Females Vectibix can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ] .",[179],{"source":32,"section":180},"8.3",1792444707598]